956121-30-5 Usage
Uses
Used in Cancer Therapy:
CRT0066101 is used as a therapeutic agent for inhibiting PDK1, which plays a critical role in cell growth and survival. This makes it a potential candidate for cancer therapy, as it may help in controlling abnormal cell growth and survival associated with cancer.
Used in Overcoming Drug Resistance in Cancer Cells:
CRT0066101 is used as a potential agent for overcoming drug resistance in cancer cells. Its ability to target PDK1 may help in enhancing the effectiveness of conventional cancer treatments and improving therapeutic outcomes in resistant cases.
Used in Drug Development and Molecular Mechanism Research:
CRT0066101 is used as a target for further investigation in drug development and the understanding of molecular mechanisms underlying cancer progression. Its potential applications in cancer therapy and overcoming drug resistance make it an important molecule for research and development of novel therapeutic strategies.
Check Digit Verification of cas no
The CAS Registry Mumber 956121-30-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,5,6,1,2 and 1 respectively; the second part has 2 digits, 3 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 956121-30:
(8*9)+(7*5)+(6*6)+(5*1)+(4*2)+(3*1)+(2*3)+(1*0)=165
165 % 10 = 5
So 956121-30-5 is a valid CAS Registry Number.
956121-30-5Relevant academic research and scientific papers
AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE
-
Page/Page column 130, (2009/10/06)
The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.
